Literature DB >> 30463873

Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit.

Julio A Huapaya1,2, Erin M Wilfong3,4, Christopher T Harden5, Roy G Brower2, Sonye K Danoff6.   

Abstract

Data on interstitial lung disease (ILD) outcomes in the intensive care unit (ICU) is of limited value due to population heterogeneity. The aim of this study was to examine risk factors for mortality and ILD mortality rates in the ICU.We performed a systematic review using five databases. 50 studies were identified and 34 were included: 17 studies on various aetiologies of ILD (mixed-ILD) and 17 on idiopathic pulmonary fibrosis (IPF). In mixed-ILD, elevated APACHE score, hypoxaemia and mechanical ventilation are risk factors for mortality. No increased mortality was found with steroid use. Evidence is inconclusive on advanced age. In IPF, evidence is inconclusive for all factors except mechanical ventilation and hypoxaemia. The overall in-hospital mortality was available in 15 studies on mixed-ILD (62% in 2001-2009 and 48% in 2010-2017) and 15 studies on IPF (79% in 1993-2004 and 65% in 2005-2017). Follow-up mortality rate at 1 year ranged between 53% and 100%.Irrespective of ILD aetiology, mechanical ventilation is associated with increased mortality. For mixed-ILD, hypoxaemia and APACHE scores are also associated with increased mortality. IPF has the highest mortality rate among ILDs, but since 1993 the rate appears to be declining. Despite improving in-hospital survival, overall mortality remains high.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30463873     DOI: 10.1183/16000617.0061-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  10 in total

1.  Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion.

Authors:  Song-I Lee; Chaeuk Chung; Dongil Park; Da Hyun Kang; Jeong Eun Lee
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

Review 2.  An Update on Systemic Sclerosis and its Perioperative Management.

Authors:  Zyad J Carr; John Klick; Brittany J McDowell; Jean G Charchaflieh; Kunal Karamchandani
Journal:  Curr Anesthesiol Rep       Date:  2020-08-29

3.  The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease.

Authors:  Peiyan Zheng; Xiaomao Zheng; Hasegawa Takehiro; Zhangkai Jason Cheng; Jingxian Wang; Mingshan Xue; Quanming Lin; Zhifeng Huang; Huimin Huang; Chenxi Liao; Baoqing Sun
Journal:  J Transl Int Med       Date:  2021-09-28

4.  Fatty acid nitroalkene reversal of established lung fibrosis.

Authors:  Adolf Koudelka; Veronika Cechova; Mauricio Rojas; Nilay Mitash; Anna Bondonese; Claudette St Croix; Mark A Ross; Bruce A Freeman
Journal:  Redox Biol       Date:  2021-12-29       Impact factor: 10.787

5.  Which factors are helpful for the early determination of treatment level in patients with interstitial lung disease in the intensive care unit to minimize the suffering in their end of life?: A retrospective study.

Authors:  Sun-Hyung Kim; Dong-Hwa Lee; Bumhee Yang; Jun Yeun Cho; Hyeran Kang; Kang Hyeon Choe; Ki Man Lee; Yoon Mi Shin
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

6.  Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics.

Authors:  Johanna P van Gemert; Inge A H van den Berk; Esther J Nossent; Leo M A Heunks; Rene E Jonkers; Alexander P Vlaar; Peter I Bonta
Journal:  BMC Pulm Med       Date:  2021-07-28       Impact factor: 3.317

7.  Outcome and prognostic factors of interstitial lung disease patients with acute respiratory failure in the intensive care unit.

Authors:  Wei-Ling Lain; Shi-Chuan Chang; Wei-Chih Chen
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

8.  Hyaluronic Acid-Decorated Liposomes as Innovative Targeted Delivery System for Lung Fibrotic Cells.

Authors:  Laura Pandolfi; Vanessa Frangipane; Claudia Bocca; Alessandro Marengo; Erika Tarro Genta; Sara Bozzini; Monica Morosini; Maura D'Amato; Simone Vitulo; Manuela Monti; Giuditta Comolli; Maria Teresa Scupoli; Elias Fattal; Silvia Arpicco; Federica Meloni
Journal:  Molecules       Date:  2019-09-10       Impact factor: 4.411

9.  Treatment Outcomes of Infectious and Non-infectious Acute Exacerbation of Myositis-Related Interstitial Lung Disease.

Authors:  Hyun Lee; Sung Jun Chung; Sang Hyuk Kim; Hayoung Choi; Youlim Kim; Tai Sun Park; Dong Won Park; Ji-Yong Moon; Sang-Heon Kim; Tae Hyung Kim; Ho Joo Yoon; Jang Won Sohn
Journal:  Front Med (Lausanne)       Date:  2022-03-07

10.  Efficacy of extracorporeal membrane oxygenation for acute respiratory failure with interstitial lung disease: a case control nationwide dataset study in Japan.

Authors:  Yuko Usagawa; Kosaku Komiya; Mari Yamasue; Kiyohide Fushimi; Kazufumi Hiramatsu; Jun-Ichi Kadota
Journal:  Respir Res       Date:  2021-07-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.